The reproductive genetics market — genetic testing technologies spanning preimplantation genetic testing (PGT), carrier screening, and prenatal diagnostics used throughout the fertility and assisted reproduction journey — is expanding rapidly as IVF utilization grows and genetic screening becomes more deeply embedded in standard fertility clinic protocols, with the Reproductive Genetics Market reflected in the PGT sub-segment alone, sized between roughly USD 590-690 million in 2025-2026 and projected by various analyst firms to reach figures ranging from just over USD 1 billion to nearly USD 1.7 billion by the early-to-mid 2030s, at compound annual growth rates generally between 7% and 10.5%. Rising IVF utilization is the foundational demand driver — in the UK, IVF now accounts for over 99% of assisted reproductive technology procedures, and in the U.S., roughly 16.6% of ART cycles currently incorporate PGT, with clinics reporting year-on-year cycle growth as patients seek greater confidence in embryo selection amid steeply age-related IVF success rates, which range from around 31% for women under 35 down to roughly 3% for women over 44. NGS technology has become the clear technical standard — next-generation sequencing has displaced older array-based comparative genomic hybridization methods as the leading PGT technology, prized for its ability to simultaneously screen multiple embryos for chromosomal abnormalities, structural variants, and single-gene mutations with greater sensitivity, including detection of segmental aneuploidies and mosaicism. Strategic partnerships are accelerating technology diffusion across reproductive genetics labs — including collaborations like Illumina's partnership with Roche to integrate NGS workflows into fertility clinic laboratories, alongside continued investment from Thermo Fisher Scientific, CooperSurgical, and Labcorp Diagnostics in assay development and lab automation. A notable headwind emerged recently in the form of legal and clinical scrutiny — a series of class-action lawsuits filed against several major PGT-A testing companies allege that some marketing overstated the accuracy and clinical predictive value of embryo aneuploidy screening, intensifying calls within the fertility field for more rigorous patient counseling around what PGT results can and cannot reliably tell prospective parents. Cost remains the primary access barrier, since PGT is frequently not fully reimbursed and adds meaningful expense on top of an already costly IVF cycle.

Do you think the recent legal scrutiny over PGT-A accuracy claims will meaningfully slow adoption growth, or will it mainly push the industry toward more conservative marketing and stronger genetic counseling standards while underlying testing volume keeps climbing?

FAQ

What is preimplantation genetic testing (PGT), and what are its main types? PGT refers to genetic testing performed on embryos created through IVF, prior to embryo transfer, to identify chromosomal or genetic abnormalities and improve the likelihood of a successful, healthy pregnancy. The main categories are PGT-A (aneuploidy screening, testing for an abnormal number of chromosomes, and the largest application segment by revenue), PGT-M (testing for specific known single-gene/monogenic disorders when parents carry a known genetic mutation), and PGT-SR (testing for structural chromosomal rearrangements in parents with a known translocation or other structural abnormality). Next-generation sequencing has become the dominant underlying technology across all three PGT types due to its accuracy and ability to detect a broader range of genetic variation than older testing methods.

Why has PGT-A adoption recently come under legal and clinical scrutiny? A series of class-action lawsuits filed in late 2024 and progressing through 2025 alleged that several major PGT-A testing companies overstated the test's accuracy and clinical predictive value in patient-facing marketing, leading some patients to make irreversible decisions — such as discarding embryos flagged as abnormal — based on information that may have been incomplete or misleading, particularly around mosaic embryo results. This scrutiny has intensified industry conversations about the gap between what patients believe PGT-A has definitively screened for versus its actual, more nuanced predictive limitations, and is pushing fertility clinics toward more rigorous, standardized genetic counseling protocols alongside continued technology adoption.

#ReproductiveGenetics #PGT #IVF #FertilityTesting #EmbryoScreening #GeneticCounseling #AssistedReproduction